Implementation and Development of Solid Organ Transplant Pharmacotherapy in Iran
Abstract
Clinical solid organ transplant (SOT) pharmacy services started half a century ago in United States (US). In 2004, United Network of Organ Sharing (UNOS) bylaws mandated all SOT programs to recognize pharmacist as a responsible for providing pharmaceutical care to SOT patients. Soon after that, SOT pharmacy services were implemented in Iran and nowadays SOT pharmacists are members of SOT multidisciplinary teams with various clinical, education, and research duties during pre-, peri-, and post-transplantation phases. Board Certification in Solid Organ Transplant Pharmacotherapy (BCTXP) was established in 2018 in the US. The aim of this postdoctoral program is providing SOT pharmacotherapy services for all patients from pre-transplantation era to decades after transplantation event in community and hospitals. Inspiring that, SOT pharmacotherapy fellowship has been programmed in Tehran University of Medical Sciences and is under consideration by National Board of Clinical Pharmacy and Ministry of Health and Medical Education of Iran. Hopefully, this program will be initiated with the first applicants among board certified clinical pharmacists from Fall 2024.
1. Mitchell JF. Pharmacist involvement as a member of a renal transplant team. Am J Hosp Pharm. 1976; 33(1):55–8.
2. Maldonado AQ, Hall RC, Pilch NA, et al. ASHP guidelines on pharmacy services in solid organ transplantation. Am J Health Syst Pharm. 2020; 77(3): 222–32.
3. Lichvar AB, Chandran MM, Cohen EA, et al. The expanded role of the transplant pharmacist: a 10-year follow-up. Am J Transplant. 2023; 23(9): 1375-87.
4. Alloway RR, Dupuis R, Gabardi S, et al. Evolution of the role of the transplant pharmacist on the multidisciplinary transplant team. Am J Transplant. 2011;11(8):1576-83.
5. Dashti-Khavidaki S, Ghaffari S, Gohari M, Khatami MR, Zahiri Z. Tacrolimus dose requirement in Iranian kidney transplant recipients within first three weeks after transplantation. Int J Organ Transplant Med. 2016; 7(3): 167-71.
6. Ghafari S, Dashti-Khavidaki S, Khatami MR, Ghahremani MH, Seyednejad SA, Beh-pajooh A. Association of CYP3A5 genetic polymorphisms with tacrolimus dose requirement and allograft outcomes in Iranian kidney transplant recipients. Iran J Kidney Dis. 2019; 13(6):414-6.
7. Nasiri-Toosi Z, Dashti-Khavidaki S, Nasiri-Toosi M, et al. Clinical pharmacokinetics of oral versus sublingual administration of tacrolimus in adult liver transplant recipients. Clin Exp Transplant. 2012; 10(6): 586-91.
8. Ghadimi M, Dashti-Khavidaki S, Khatami MR, et al. Comparing the effect of immediate versus delayed initiation of tacrolimus on delayed graft function in kidney transplant recipients: a randomized open-label clinical trial. J Res Pharm Pract. 2018; 7(2):69-76.
9. Dashti-Khavidaki S, Saidi R, Lu H. Current status of glucocorticoid usage in solid organ transplantation. World J Transplant. 2021;11(11):443-65.
10. Dashti-Khavidaki S, Baradaran H, et al. Comprehensive pharmacotherapy protocol for liver transplant recipients. 1st ed. Tehran. Etminan Publication. 2022. (Persian language).
11. Dashti-Khavidaki S, Moghadamnia M, et al. Comprehensive pharmacotherapy protocol for pediatric liver transplant recipients. 1st ed. Tehran. Etminan Publication. 2023. (Persian language).
12. Dashti-Khavidaki S, Mohammadi K, Khatami MR. Comprehensive protocol for pharmacotherapy of kidney transplant patients. 1st ed. Tehran. Etminan Publication. 2020. (Persian Language).
13. Dashti-Khavidaki S, Laki B, et al. Comprehensive protocol for pharmacotherapy of simultaneous kidney and pancreas transplant patients. 1st ed. Tehran. Etminan Publication. 2021. (Persian language).
14. Moghadamnia M, Eshaghi H, Alimadadi H, Dashti-Khavidaki S. A quick algorithmic review on management of viral infectious diseases in pediatric solid organ transplant recipients. Front Pediatr. 2023; 11: 1252495.
15. Mohammadi K, Khajeh B, Dashti-Khavidaki S, Shab-bidar S. Association between cumulative rATG induction doses and kidney graft outcomes and adverse effects in kidney transplant patients: a systematic review and meta-analysis. Exp Opin Biol Ther. 2021; 21(9): 1265-79.
16. Jafari A, Najivash P, Khatami MR, Dashti‑Khavidaki S. Cytopenia occurrence in kidney transplant recipients within early post-transplant period. J Res Pharm Pract. 2017; 6(1):31-9.
17. Gharekhani A, Entezari-Maleki T, Khalili H, Dashti-Khavidaki S. A review on comparing two commonly used rabbit anti-thymocyte globulins as induction therapy in solid organ transplantation. Exp Opin Biol Ther. 2013;13(9): 1299-313.
18. Baradaran H, Hashem Zadeh A, Dashti-Khavidaki S, Laki B. Management of drug-induced neutropenia, thrombocytopenia, and anaemia after solid organ transplantation: a comprehensive review. J Clin Pharm Ther. 2022; 47(12): 1895-912.
19. Ahmadi F, Dashti-Khavidaki S, Khatami MR, Lessan-Pezeshki M, Khalili H, Khosravi M. Rituximab related late onset neutropenia in kidney transplant recipients treated for antibody-mediated acute rejection. Exp Clin Transplant. 2017; 15(4):414-9.
20. Ghadimi M, Mohammadpour Z, Dashti-Khavidaki S, Milajerdi A. m-TOR inhibitors and risk of Pneumocystis pneumonia after solid organ transplantation: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2019; 75(11): 1471-80.
21. Ghadimi M, Dashti-Khavidaki S, Shahali M, Gohari M, Khatami MR, Alamdari A. Tacrolimus interaction with oral oestrogen in kidney transplant recipients: A case-control study. J Clin Pharm Ther. 2018; 43(4): 513-8.
22. Lexi-interact. Lexicomp. August 2023.
23. Labbani-Motlagh Z, Dashti-Khavidaki S. Reconsideration of interaction between direct oral anticoagulants and calcineurin inhibitors. Journal of Pharmaceutical Care. 2020; 8(2): 88-9.
24. Baradaran H, Dashti-Khavidaki S, Taher M, Talebian M, Nasiri-Toosi M, Jafarian A. Antibody-mediated rejection in adult liver transplant recipients: a case series and literature review. J Clin Pharmacol. 2022; 62(2): 254-71.
25. Dashti-Khavidaki S, Shojaie L, Hosni A, Khatami MR, Jafari A. Effectiveness of IVIG plus plasmaphresis on antibody-mediated rejection or thrombotic microangiopathy in Iranian kidney transplant recipient. Nephrourol Mon. 2015; 7(3):e27073.
26. Nabiee M, Vahidfar N, Dashti-Khavidaki S, et al. Discordance in drug dosing using estimated versus measured glomerular filtration rate in kidney transplant recipients. Iran J Kidney Dis. 2021; 15(3): 213-21.
27. Nabiee M, Dashti-Khavidaki S. Donor’s versus recipient’s demographic data for estimating kidney function in kidney transplant recipients. J Res Pharm Pract. 2019; 8(3): 179-80.
28. Saee Y, Ahmadinejad Z, Ghiasvand F, Dashti-Khavidaki S. Comparing two equations for estimation of kidney function (Cockcroft- Gault and Glomerular Filtration Rate Assessment in Liver Disease) for vancomycin dosing in adult liver transplant recipients: a pilot, randomized clinical trial. Pharmaceutical Sciences. 2022; 28(3): 427-33.
29. Laki B, Dashti-Khavidaki S, Baradaran H, Fakhar N. Thromboprophylaxis challenge after pancreas transplantation: a literature review. Int J Organ Transplant Med. 2022; 13 (4): 41-51.
30. Mohammadi K, Yaribash S, Razi B, Dashti-Khavidaki S. Comparing safety of proton-pump inhibitors versus H2-receptor antagonists in kidney transplant recipients: A systematic review and meta-analysis. J Clin Pharm Ther. 2022; 47(5): 567-74.
31. Borran M, Dashti-Khavidaki S, Alamdari A, Naderi N. Vitamin C and kidney transplantation: nutritional status, potential efficacy, safety, and interactions. Clin Nutr ESPEN. 2021; 41: 1-9.
32. Monfared A, Dashti-Khavidaki S, Jafari R, et al. Clinical characteristics and outcome of COVID-19 pneumonia in kidney transplant recipients in Razi hospital, Rasht, Iran. Transpl Infect Dis. 2020; 22(6): e13420.
33. Dashti-Khavidaki S, Mohammadi K, Khalili H, Abdollahi A. Pharmacotherapeutic considerations in solid organ transplant patients with COVID-19. Expert Opin Pharmacother. 2020; 21(15): 1813-9.
2. Maldonado AQ, Hall RC, Pilch NA, et al. ASHP guidelines on pharmacy services in solid organ transplantation. Am J Health Syst Pharm. 2020; 77(3): 222–32.
3. Lichvar AB, Chandran MM, Cohen EA, et al. The expanded role of the transplant pharmacist: a 10-year follow-up. Am J Transplant. 2023; 23(9): 1375-87.
4. Alloway RR, Dupuis R, Gabardi S, et al. Evolution of the role of the transplant pharmacist on the multidisciplinary transplant team. Am J Transplant. 2011;11(8):1576-83.
5. Dashti-Khavidaki S, Ghaffari S, Gohari M, Khatami MR, Zahiri Z. Tacrolimus dose requirement in Iranian kidney transplant recipients within first three weeks after transplantation. Int J Organ Transplant Med. 2016; 7(3): 167-71.
6. Ghafari S, Dashti-Khavidaki S, Khatami MR, Ghahremani MH, Seyednejad SA, Beh-pajooh A. Association of CYP3A5 genetic polymorphisms with tacrolimus dose requirement and allograft outcomes in Iranian kidney transplant recipients. Iran J Kidney Dis. 2019; 13(6):414-6.
7. Nasiri-Toosi Z, Dashti-Khavidaki S, Nasiri-Toosi M, et al. Clinical pharmacokinetics of oral versus sublingual administration of tacrolimus in adult liver transplant recipients. Clin Exp Transplant. 2012; 10(6): 586-91.
8. Ghadimi M, Dashti-Khavidaki S, Khatami MR, et al. Comparing the effect of immediate versus delayed initiation of tacrolimus on delayed graft function in kidney transplant recipients: a randomized open-label clinical trial. J Res Pharm Pract. 2018; 7(2):69-76.
9. Dashti-Khavidaki S, Saidi R, Lu H. Current status of glucocorticoid usage in solid organ transplantation. World J Transplant. 2021;11(11):443-65.
10. Dashti-Khavidaki S, Baradaran H, et al. Comprehensive pharmacotherapy protocol for liver transplant recipients. 1st ed. Tehran. Etminan Publication. 2022. (Persian language).
11. Dashti-Khavidaki S, Moghadamnia M, et al. Comprehensive pharmacotherapy protocol for pediatric liver transplant recipients. 1st ed. Tehran. Etminan Publication. 2023. (Persian language).
12. Dashti-Khavidaki S, Mohammadi K, Khatami MR. Comprehensive protocol for pharmacotherapy of kidney transplant patients. 1st ed. Tehran. Etminan Publication. 2020. (Persian Language).
13. Dashti-Khavidaki S, Laki B, et al. Comprehensive protocol for pharmacotherapy of simultaneous kidney and pancreas transplant patients. 1st ed. Tehran. Etminan Publication. 2021. (Persian language).
14. Moghadamnia M, Eshaghi H, Alimadadi H, Dashti-Khavidaki S. A quick algorithmic review on management of viral infectious diseases in pediatric solid organ transplant recipients. Front Pediatr. 2023; 11: 1252495.
15. Mohammadi K, Khajeh B, Dashti-Khavidaki S, Shab-bidar S. Association between cumulative rATG induction doses and kidney graft outcomes and adverse effects in kidney transplant patients: a systematic review and meta-analysis. Exp Opin Biol Ther. 2021; 21(9): 1265-79.
16. Jafari A, Najivash P, Khatami MR, Dashti‑Khavidaki S. Cytopenia occurrence in kidney transplant recipients within early post-transplant period. J Res Pharm Pract. 2017; 6(1):31-9.
17. Gharekhani A, Entezari-Maleki T, Khalili H, Dashti-Khavidaki S. A review on comparing two commonly used rabbit anti-thymocyte globulins as induction therapy in solid organ transplantation. Exp Opin Biol Ther. 2013;13(9): 1299-313.
18. Baradaran H, Hashem Zadeh A, Dashti-Khavidaki S, Laki B. Management of drug-induced neutropenia, thrombocytopenia, and anaemia after solid organ transplantation: a comprehensive review. J Clin Pharm Ther. 2022; 47(12): 1895-912.
19. Ahmadi F, Dashti-Khavidaki S, Khatami MR, Lessan-Pezeshki M, Khalili H, Khosravi M. Rituximab related late onset neutropenia in kidney transplant recipients treated for antibody-mediated acute rejection. Exp Clin Transplant. 2017; 15(4):414-9.
20. Ghadimi M, Mohammadpour Z, Dashti-Khavidaki S, Milajerdi A. m-TOR inhibitors and risk of Pneumocystis pneumonia after solid organ transplantation: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2019; 75(11): 1471-80.
21. Ghadimi M, Dashti-Khavidaki S, Shahali M, Gohari M, Khatami MR, Alamdari A. Tacrolimus interaction with oral oestrogen in kidney transplant recipients: A case-control study. J Clin Pharm Ther. 2018; 43(4): 513-8.
22. Lexi-interact. Lexicomp. August 2023.
23. Labbani-Motlagh Z, Dashti-Khavidaki S. Reconsideration of interaction between direct oral anticoagulants and calcineurin inhibitors. Journal of Pharmaceutical Care. 2020; 8(2): 88-9.
24. Baradaran H, Dashti-Khavidaki S, Taher M, Talebian M, Nasiri-Toosi M, Jafarian A. Antibody-mediated rejection in adult liver transplant recipients: a case series and literature review. J Clin Pharmacol. 2022; 62(2): 254-71.
25. Dashti-Khavidaki S, Shojaie L, Hosni A, Khatami MR, Jafari A. Effectiveness of IVIG plus plasmaphresis on antibody-mediated rejection or thrombotic microangiopathy in Iranian kidney transplant recipient. Nephrourol Mon. 2015; 7(3):e27073.
26. Nabiee M, Vahidfar N, Dashti-Khavidaki S, et al. Discordance in drug dosing using estimated versus measured glomerular filtration rate in kidney transplant recipients. Iran J Kidney Dis. 2021; 15(3): 213-21.
27. Nabiee M, Dashti-Khavidaki S. Donor’s versus recipient’s demographic data for estimating kidney function in kidney transplant recipients. J Res Pharm Pract. 2019; 8(3): 179-80.
28. Saee Y, Ahmadinejad Z, Ghiasvand F, Dashti-Khavidaki S. Comparing two equations for estimation of kidney function (Cockcroft- Gault and Glomerular Filtration Rate Assessment in Liver Disease) for vancomycin dosing in adult liver transplant recipients: a pilot, randomized clinical trial. Pharmaceutical Sciences. 2022; 28(3): 427-33.
29. Laki B, Dashti-Khavidaki S, Baradaran H, Fakhar N. Thromboprophylaxis challenge after pancreas transplantation: a literature review. Int J Organ Transplant Med. 2022; 13 (4): 41-51.
30. Mohammadi K, Yaribash S, Razi B, Dashti-Khavidaki S. Comparing safety of proton-pump inhibitors versus H2-receptor antagonists in kidney transplant recipients: A systematic review and meta-analysis. J Clin Pharm Ther. 2022; 47(5): 567-74.
31. Borran M, Dashti-Khavidaki S, Alamdari A, Naderi N. Vitamin C and kidney transplantation: nutritional status, potential efficacy, safety, and interactions. Clin Nutr ESPEN. 2021; 41: 1-9.
32. Monfared A, Dashti-Khavidaki S, Jafari R, et al. Clinical characteristics and outcome of COVID-19 pneumonia in kidney transplant recipients in Razi hospital, Rasht, Iran. Transpl Infect Dis. 2020; 22(6): e13420.
33. Dashti-Khavidaki S, Mohammadi K, Khalili H, Abdollahi A. Pharmacotherapeutic considerations in solid organ transplant patients with COVID-19. Expert Opin Pharmacother. 2020; 21(15): 1813-9.
| Files | ||
| Issue | Vol 11, No 4 (Autumn 2023) | |
| Section | Editorial | |
| DOI | https://doi.org/10.18502/jpc.v11i4.16015 | |
| Keywords | ||
| Clinical pharmacy; Pharmacotherapy; Solid organ transplant pharmacist; SOT pharmacotherapy; Transplant pharmacist | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Dashti-Khavidaki S. Implementation and Development of Solid Organ Transplant Pharmacotherapy in Iran. J Pharm Care. 2023;11(4):195-199.
